Harris Todd 4

What Happened

• Harris Todd, President, CEO and a director of Tyra Biosciences (TYRA), received two equity awards on May 5, 2026: 79,000 RSUs and an additional 265,000 RSU-type derivative awards (total 344,000). Both grants were reported at $0.00 per share (no cash paid).
• These are awards (code A) — not open-market purchases or sales — and represent contingent rights to receive common stock if and when the awards vest.

Key Details

• Transaction date: May 5, 2026; Form 4 filed May 7, 2026 (within the normal 2-business-day reporting window).
• Award amounts and prices: 79,000 shares @ $0.00 (RSU grant); 265,000 shares @ $0.00 (derivative RSU grant). Total awarded: 344,000 RSUs; reported value = $0 at grant.
• Shares owned after transaction: Not specified in the excerpts provided.
• Notable footnotes:
  • F1: The RSUs (granted May 5, 2026) vest 25% on each of the first four anniversaries of May 5, 2026, subject to continued service; each RSU converts into one share upon vesting.
  • F2: Confirms the 265,000 amount includes RSUs.
  • F3: Notes a separate monthly vesting schedule (1/48th monthly after May 5, 2026) for option-style awards if applicable.
• Filing timeliness: Reported May 7 for a May 5 transaction — appears timely under standard Form 4 rules.

Context

• RSUs are a form of compensation that convert into shares only when they vest; they are not an immediate market purchase or sale and do not imply immediate insider buying or selling.
• For retail investors, awards like these signal executive compensation alignment with shareholders but do not represent an immediate change in insider share ownership until vesting occurs.